A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management
This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.
Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Izaak Woodley
- Email: izaakwoodley@thecollagen.co
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89101
- Citruslabs
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18-55 years at the time of enrollment.
- Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
- Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
- Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
- Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
- In good general health.
- Resides in the United States.
Exclusion Criteria:
- Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
- Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
- Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
- Currently testing, or plan to in the next 12 weeks, a product for another research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Glow Shakes Premium Collagen Meal Replacement Arm
|
Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Perceived Nutritional Adequacy
Time Frame: Baseline to Week 12
|
Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire |
Baseline to Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Fat Percentage
Time Frame: Baseline to Week 12
|
Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Muscle Mass
Time Frame: Baseline to Week 12
|
Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale |
Baseline to Week 12
|
|
Change in Self-Reported Weight Management and Food Cravings
Time Frame: Baseline to Week 12
|
Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Smoothness
Time Frame: Baseline to Week 12
|
Within-participant change in perceived skin smoothness score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Perceived Skin Elasticity
Time Frame: Baseline to Week 12
|
Within-participant change in perceived skin elasticity score assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hunger Intensity
Time Frame: Baseline to Week 12
|
Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Satiety Duration
Time Frame: Baseline to Week 12
|
Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument |
Baseline to Week 12
|
|
Change in Self-Reported Food Craving Scores
Time Frame: Baseline to Week 12
|
Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced) |
Baseline to Week 12
|
|
Change in Self-Reported Hair Thickness
Time Frame: Baseline to Week 12
|
Within-participant change in perceived hair thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Hair Health
Time Frame: Baseline to Week 12
|
Within-participant change in perceived hair health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Energy Levels
Time Frame: Baseline to Week 12
|
Within-participant change in perceived energy levels assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Cognitive Focus
Time Frame: Baseline to Week 12
|
Within-participant change in perceived cognitive focus assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Thickness
Time Frame: Baseline to Week 12
|
Within-participant change in perceived nail thickness assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Nail Health
Time Frame: Baseline to Week 12
|
Within-participant change in perceived nail health assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Gut Comfort and Digestive Health
Time Frame: Baseline to Week 12
|
Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Metabolism Support
Time Frame: Baseline to Week 12
|
Within-participant change in perceived metabolism support assessed via self-report questionnaire |
Baseline to Week 12
|
|
Change in Self-Reported Physical Strength
Time Frame: Baseline to Week 12
|
Within-participant change in perceived physical strength assessed via self-report questionnaire |
Baseline to Week 12
|
|
Product Tolerability and Participant Satisfaction
Time Frame: Week 12
|
Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire |
Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- THECO-73657
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.